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Background: Psoriasis is a chronic hereditary inflammatory disease that can affect both the skin and 
joints, and affects 2-3 % of the world‟s population. It presents with red and inflamed thick skin that 
has flaky silver-white patches, and 60% of those who suffer from it report it to be a large problem in 
their everyday life. Fish oils contain the omega-3 fatty acids EPA and DHA, which are precursors to 
eicosanoids that have been seen to reduce inflammation. As psoriasis is an inflammatory disorder, the 
supplementation of fish oils is hypothesised to improve patients symptoms and therefore also their 
quality of life. 
 
Objective: The aim of this paper is to review the literature and evaluate whether or not the oral 
supplementation of fish oils for symptom alleviation is recommended in psoriasis.  
 
Search strategy: The literature search was conducted through the databases PubMed, Scopus and 
Cochrane. In Pubmed and Scopus, the keywords used were “psoriasis and fish oil”, “psoriasis and 
omega 3”, “psoriasis and EPA” and “psoriasis and DHA”. In Cochrane, the words “Psoriasis and fish 
oil” were used.  
 
Selection criteria: The criteria were that the studies were to be randomized controlled trials conducted 
on humans written in English. The supplementation of fish oils should be oral and the condition 
should be psoriasis. No time limits when the studies were made were included.  
 
Data collection and analysis: Three RCTs were identified in the literature search. These studies were 
examined using the template “Review template for randomized controlled trials” (granskningsmall för 
randomiserad kontrollerad prövning) and the selected outcomes were analysed according to the 
GRADE-system using the template “conclusive evidence form” (Sammanfattande evidensformulär). 
The outcomes measured were inflammation in form of erythema and coverage in form of affected 
area.  
 
Main results: The outcome measures in two of the studies shows no statistic significant improvement 
of symptoms after the oral supplementation of fish oils. One of the studies showed a small but 
significant improvement in inflammation and a trend towards an improvement in the surface area 
affected. Both the outcome for inflammation and coverage ended up having a limited (++) evidence 
grade. 
 
Conclusions: The clinical value of fish oil supplementation remains uncertain. Fish oil 
supplementation may possibly exert some positive effects when used in addition to established 
psoriatic therapies, but at present its use as an exclusive treatment is not justifiable. Both higher doses 
of fish oils and longer periods should be examined in double blind studies in the future. 
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Bakgrund: Psoriasis är en kronisk ärftlig inflammatorisk sjukdom som kan drabba huden såväl som 
lederna. 2-3 % av jordens befolkning uppskattas vara drabbade. Sjukdomen uppvisar röd och 
förtjockad inflammerad hud med silvervita flagor. 60% av de drabbade upplever sjukdomen orsakar 
svårigheter i deras vardagliga liv. Fiskolja innehåller omega-3 fettsyrorna EPA och DHA, två 
förstadier till eikosanoider som har en påvisad anti-inflammatorisk effekt. Då psoriasis är en 
inflammatorisk sjukdom, skulle ett tillskott av fiskolja kunna förbättra symtombilden och därmed 
även patienternas livskvalitet.   
 
Syfte: Syftet med denna översikt är att undersöka om ett oralt tillskott med fiskolja förbättrar 
symtombilden i psoriasis.  
Sökväg: Vid litteratursökningen användes databaserna PubMed, Scopus och Cochrane. I PubMed och 
Scopus användes sökorden ”psoriasis and fish oil”, ”psoriasis and omega 3”, ”psoriasis and EPA” och 
”psoriasis and DHA”. I Cochrane användes sökorden ”psoriasis and fish oil”.  
  
Urvalskriterier: Urvalskriterierna var att studierna skulle vara Randomiserade kontrollerade 
prövningar utförda på människor. De skulle vara skrivna på engelska. Tillskottet av fiskoljan skulle 
vara oralt och diagnosen psoriasis. Ingen tidsbegränsning på när studierna var gjorda sattes. 
 
Datainsamling och analys: Efter sökning i ovanstående sökmotorer med nämnda sökord 
identifierades tre stycken RCT. Studierna granskades enligt mallen ”Granskningsmall för 
randomiserad kontrollerad prövning” och de valda effektmåtten analyserades enligt GRADE-systemet 
med hjälp av ”sammanfattande evidensformulär”.  
 
Resultat: De två effektmåtten visade i två av studierna ingen signifikant förbättring vid tillskott av 
fiskolja. I en av studierna visades en liten men statistiskt signifikant förbättring av erytem och en 
tendens till förbättring av täckt hudyta. De två effektmåtten för inflammation samt täckning fick 
evidensstyrkan begränsad (++). 
 
Slutsats: Den kliniska betydelsen av fiskoljetillskott är osäker. Supplementering av fiskolja kan ha 
viss positiv effekt i kombination med övriga behandlingar för psoriasis, men för tillfället finns det inte 
tillräcklig evidens för att det ska rekommenderas som primär behandling av sjukdomen. Högre 
dosering av fiskolja och längre prövningstid bör undersökas i dubbelblinda studier i framtiden.  
 
Abbreviations 
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DHA – Docosahexaenoic acid 
 
EPA – Eicosapentaenoic acid 
 
IU – International Unit  
 
MUFA – Monounsaturated fatty acid  
 
PASI – Psoriasis Area and Severity Index 
 
PUFA – Polyunsaturated fatty acid 
 
SBU - The Swedish Council on Health Technology Assessment   
 
SFA – Saturated fatty acid 
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Introduction 
 
Psoriasis 
Psoriasis is a chronic hereditary inflammatory disease that can affect both the skin and joints. 
It is one of the most common endemic diseases in Sweden. According to the Swedish 
Psoriasis association, 250 000-300 000 swedes, 2-3% of the population, suffer from a sort of 
psoriasis (1). Worldwide, this number is 125 million, similarly 2-3% (2). It is just as common 
in men as well as in women and it often appears between the ages of 15 and 25 (2). It is a 
reoccurring disease that is triggered by a range of factors; weather, smoking, alcohol and 
stress being the most common (5).  
 
Psoriasis in the skin presents with red and inflamed thick skin that has flaky silver-white 
patches known as scales (3). The redness of the skin, known as erythema, is caused by 
inflammation that arises as a result of accumulation of immune cells and chemicals that these 
cells release (16). Plaque-type psoriasis, which is characterized by round erythematous raised 
plaques with silvery scale, is the most common form comprising 90% of all cases (4).  Other 
types of psoriasis include guttate psoriasis, pustular psoriasis and inverse psoriasis (7).  
 
Nearly 60 percent of people suffering of psoriasis reported their disease to be a large problem 
in their everyday life. Patients with moderate to severe psoriasis often experience a large 
negative impact on their quality of life. (2)  
 
The severity of psoriasis is often measured using the standardized Psoriasis and Severity 
Index or PASI. This index quantifies sclerosis (hardening of a tissue or an increase of 
connective tissue (12)), erythema, scale and extent of body surface area involvement in four 
body regions – these being the head and neck, trunk, upper extremities and lower extremities. 
(4)   
 
Primary treatment of psoriasis consists of topical ointments and moisturizing creams with or 
without steroids and vitamin D derivatives, ultraviolet light therapy or steroid infusions (6).  
 
There have been many „natural remedies‟ that lay claim to being able to help or treat 
psoriasis. Most have little to no scientific basis and are based on theory rather than clinical 
trials. Natural medical practitioners have advised some of the following treatments for these 
patients: Dead sea salt, specialised diets (for example a diet low in saturated fats as these 
have been seen to exude an inflammatory effect), homeopathy, herbs, lifestyle changes- 
including physical activity, meditation, weight loss, and a reduced stress lifestyle. (25)  
 
The biochemical and physiological effect of fish oil 
Fish oils are derived from the tissues of oily fish and contain the omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA are 
precursors of eicosanoids that have been seen to reduce inflammation. (11) 
 
Omega 6 fatty acids are another branch of unsaturated fatty acids that, similarly to omega 3 
fatty acids are essential to the human body. The main sources of omega-6 acids are corn-, 
sunflower- and rapeseed oil. (25)  
 
Fish oils can be acquired through eating fish or taking supplements. A lot of the benefit 
seems to come from the omega-3 fatty acids they contain (10). Fish that are especially rich in 
these omega-3 fatty acids are mackerel, tuna and salmon (10).  Supplements with fish oil 
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usually contain small amounts of vitamin E to prevent the oils from becoming rancid (10). 
Side effects seen from the supplementation of fish oils include belching, bad breath, 
heartburn, nausea, loose stools, rashes and nosebleeds, sometimes affecting the outcome of 
clinical trials evaluating the effect of these oils (8).  
 
Omega-3 fatty acids, particularly EPA, have a similar chemical structure to aracadonic acid 
(AA) and partially replace this acid in epidermal and blood cell membrane lipid composition. 
AA is found in high levels the skin lesions seen in psoriasis and leukotriene B4, one if its 
metabolites, is thought to act as a mediator of inflammation in this disease. When EPA is 
metabolized in place of AA in the cell membranes, this has been seen to help mitigate 
inflammation, as the metabolites of EPA are less potent inflammatory mediators than those of 
AA. (17)  
 
Further, they modulate enzymatic activity and membrane receptors as well as have 
antithrombotic and immuno-modulating properties that have been seen to improve 
inflammatory conditions (17). They have also been seen to supress the production of pro-
inflammatory cytokines that are usually raised in patients with inflammatory disorders. (3, 
19, 20)  
 
The level of anti-inflammatory activity may vary among different fish oil supplements 
depending on the concentration of EPA, as this fatty acid is involved in the anti-inflammatory 
pathway of fish oils in cells (17). Further, essential fatty acids are involved in our skins 
protective moisture lipid barrier and as this protective barrier is frequently disrupted by 
inflammation, fish oils help restore the cell wall integrity (3). DHA similarly exhibits an anti-
inflammatory effect, however it is not specific to the mechanism of inflammation seen in 
psoriasis (30). Not only does it decreases the risk of thrombosis in the blood, but has been 
seen to be beneficial in depression, cardiovascular disease and visual acuity (30).  
 
There is strong evidence that the supplementation of fish oils can reduce high blood pressure, 
hypertriglyceridemia and reduce the risk of cardiovascular disease (9). There have been a 
number of low quality trials conducted on the effect of fish oils in psoriasis that show a 
positive outcome; however, they have not provided enough evidence to conclude whether or 
not they are recommended in this group of patients (17).  
 
Problem 
Psoriasis causes much discomfort, embarrassment and angst for people who suffer of this 
disease (2). It becomes increasingly important to find methods to help alleviate the symptoms 
and help with the improvement of the overall condition. In addition to prescriptive drug use, 
lifestyle and diet changes, it is important to investigate whether a nutritional supplement can 
have a positive effect on the overall disease state and quality of life for the patients.  
 
Objective 
The aim of this paper is to review the literature and evaluate whether or not the oral 
supplementation of fish oils for symptom improvement is recommended in psoriasis. 
 
Issue 
  Can the regular oral supplementation of fish oil improve symptoms, in form of 
inflammation and coverage, in psoriasis? 
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Methodology 
 
Inclusion and exclusion criteria 
This thesis is based on a literature search. As there is a lot of research on the effect of fish oils 
and omega-3 fatty acids on psoriasis, inclusion and exclusion criteria were set to make the 
search more specific (17). It was decided that the studies were to be randomized controlled 
trials (RCT) conducted on humans, the supplementation of fish oils was to be oral and the 
articles were to be written in English. Further, the parameters that were looked at for subjects 
included in the studies were age, sex, type and stage of psoriasis, treatment history as well as 
the incidence of other medical conditions. As psoriasis is a disease that affects people of all 
ages and men and woman to the same extent, no age limit or sex specificity was set (12). 
Studies on all types of psoriasis were accepted but those involving patients with similar 
dermatological conditions were excluded. No time limit for when the studies were conducted 
or their duration was set.  
 
Collection of Data  
The literature search can be followed in table 1. 
Table 1. Data collection. Where and how the literature search was conducted. 
DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, RCT: Randomized controlled trial 
 
 
Database Date Search words, 
free search 
Limitations Hits  Chosen articles 
(duplicates) 
Pubmed 21st February Psoriasis AND 
Fish oil 
Humans, RCT 18 3 
Pubmed 21st February Psoriasis AND 
omega 3  
Humans, RCT 13 (3) 
Pubmed 21st February Psoriasis AND 
DHA  
Humans, RCT 4 0 
Pubmed 21st February Psoriasis AND 
EPA  
Humans, RCT 7 0 
Scopus 21st February Psoriasis AND 
Fish oil AND 
randomized 
controlled trial 
 11 (2) 
Scopus 21st February Psoriasis AND 
omega 3 AND 
randomized 
controlled trial  
 8 0 
Scopus 21st February Psoriasis AND 
DHA AND 
randomized 
controlled trial 
 2 0 
Scopus 21st February Psoriasis AND 
EPA AND 
randomized 
controlled trial 
 2 0 
Cochrane 
Library  
23rd February Psoriasis AND 
fish oil 
Trials 28 (3) 
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The search for articles was conducted in PubMed, Scopus and in the Cochrane Library via 
the Gothenburg University library. The search in PubMed was limited to humane studies and 
Randomized controlled trials. The search words that were used were “psoriasis and fish oil”, 
“psoriasis and omega 3”, “psoriasis and DHA” as well as “psoriasis and EPA”. Titles and 
abstracts for all hits were read and those articles that matched our demands for inclusion – 
three of them - were chosen. Those studies excluded after reading the titles and abstracts 
were not relevant to our subject as they looked at infusions of fish oils, topical treatment with 
fish oils and combination therapies. Three RCT‟s conducted on humans, that prior to the in-
depth assessment were thought to be of high quality, were chosen. The authors to these three 
trials were Bittiner et al (13), Søyland et al (14) and Bjørneboe et al (15).  
  
Processing of data  
To begin with, the studies were assessed through the reading of their titles abstracts and it 
was decided whether or not they were relevant for this review. A template from The Swedish 
Council on Health Technology Assessment (SBU) was used (see Appendix 1).  The criteria 
that had to be fulfilled were adequacy and relevance of the population, inclusion and 
exclusion criteria, a relevant intervention and control group as well as an adequate duration of 
the study. Further, the outcomes measured had to be of clinical relevance. The three studies 
(13-15) that met the inclusion criteria were classed as relevant.    
 
Once the studies were classed as relevant and fit the selection criteria, the quality of them was 
evaluated. This was done with the help of another template from SBU. This template (see 
Appendix 2) allowed us to assess the quality of the separate studies by assessing the level of 
accuracy and information given regarding selection bias, performance bias, detection bias, 
attrition, reporting bias, other considerations such as conflicts of interest and indirectness of 
evidence. After evaluating the studies on each of these points, a judicial and comprehensive 
decision was made regarding their quality; high, average or low.    
 
Analysis of the outcomes 
Once the relevant studies were chosen, appropriate outcomes were identified. The two 
outcomes that were chosen were erythema for inflammation and surface area for coverage. 
The reasons behind theses choices include the facts that inflammation is an indicator of the 
severity of the disease, and coverage is a symptom that patients perceive as very 
embarrassing and difficult to live with (2).  
 
The two outcomes were analyzed and evidence graded according to the GRADE-system, 
using the template “ conclusive evidence-form” from the University of Gothenburg (appendix 
3). The strength of evidence for the outcomes inflammation, in form of erythema, and 
coverage, in form of affected area, were assessed using this template.   
 
Results 
 
A double blind randomized placebo-controlled trial of fish oils in psoriasis, Bittiner et al 
(13). 
Tables 3, 4 and 5 present the results of the different trials. The trial conducted by Bittiner et 
al (13) was a double blind placebo controlled RCT. 32 patients with chronic stable plaque 
psoriasis were entered into this trial that aimed to investigate what effect the consumption of 
ten 1g capsules of fish oil MaxEpa
®
, consuming 1.8g of EPA daily, would have on itching, 
erythema, scaling and area. MaxEpa
®
 capsules are composed of ethyl esters of omega-3.  The 
effect was compared to that in a control group that received ten 1g capsules of olive oil/day. 
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All patients were instructed to continue with their usual topical treatment. If there had 
recently been any alterations in this treatment the patients were excluded from the trial.  
 
The subjects were randomly allocated to receive either the fish oil or the olive oil. The 
capsules were indistinguishable and both contained peppermint oil to disguise the taste. The 
trial lasted for twelve weeks with assessments by the same observer at baseline, four, eight 
and twelve weeks. Erythema and scaling was assessed by a clinician on a 0-5 point grading 
system. The surface area was measured in a percentage of total body surface area and the 
itching on a subjective scale of 0-5 by the patient. The assessments took place in in a room 
with no outside windows to standardize the conditions. Compliance was measured by capsule 
counting and by assay of erythrocyte membrane lipids with liquid chromatography. Four 
patients were lost to follow up at eight weeks and another four at twelve weeks. One patient 
dropped out of the placebo group at week four as a treatment failure. 28 (88%) and 24 (75%) 
of the subjects completed eight and twelve weeks respectively. The patients that completed 
the trial were well matched for age, sex, disease duration and type of topical treatment.   
 
At eight and twelve weeks, there was a significant improvement as regards to erythema in the 
intervention group (p<0.05). There was no change in the placebo group. The percentage 
surface area affected showed a trend towards improvement in the MaxEpa
®
 group at twelve 
weeks. However, this trend did not attain statistical significance.  
 
Quality assessment 
The double-blind randomized placebo-controlled trial by Bittiner et al (13) was assessed to be 
of average quality. Reasons behind this decision were that 25% of the subjects did not fulfill 
the trial and that the reasons behind this were not stated. Further, the subjects continued with 
their usual topical treatments and these varied between the intervention group and the control 
group, possibly affecting the results. The population size and duration were not very large, 
decreasing this trials statistical power. However, all participants and clinicians were blinded, 
compliance was high and all of the relevant outcomes were measured, still giving this trial an 
average quality.  
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Table 2. Result of trial conducted by Bittiner et al (13).  
 
C: Control; I: Intervention; RCT: Randomised controlled trial 
 
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with 
psoriasis, Søyland et al (14).   
The trial conducted by Søyland et al (14) was a four-month double blind multi-center trial 
aiming at investigating the effect of dietary supplementation with very-long-chain omega-3 
fatty acids in patients with psoriasis. 145 patients with moderate to severe psoriasis were 
assigned to receive either six 1g capsules of fish oils or six capsules of corn oil, mainly 
composing of omega-6 acids. The fish oil capsules altogether contained 3g of EPA. Further, 
both the fish oil capsules and the corn oil capsules contained 3.6 IU of vitamin E. The results 
of this study are summarized in table 4 below.  
 
The subjects were examined before the trial and once a month thereafter by the same 
clinician. Erythema, infiltration, desquamation and the area of skin involved were scored by 
this clinician and summed to produce a score on the Psoriasis Area and Severity Index 
(PASI).  
 
124 (86%) patients, 62 in each group completed the trial. Out of the 124 subjects, 44 were 
women (35%) and 80 were men (65%), the mean age being 47 years. Ten patients in the fish 
oil group and eleven in the corn oil group withdrew due to demands placed on them, acute 
clinical exacerbations requiring treatment, a move to another area or the inability to swallow 
the capsules. Compliance was good, as evaluated through capsule count and the measuring of 
the fatty acid composition of serum phospholipids prior to and after the trial.  
 
The patients were advised to decrease their intake of saturated fatty acids (SFA) by reducing 
their intake of full-fat milk products, hard margarine and meat. They received written and 
oral information on foods high in SFA. The dietary intake of SFA was assessed before and 
Author/s Study 
design 
Population Intervention Coverage Inflammation Other  Quality 
Bittiner 
et al, 
1988, 
England  
Double-
blind 
placebo 
controlled 
RCT 
32 patients 
with stable 
chronic 
psoriasis 
 
16 female 
12 male  
 
Mean age 
35.6yrs 
I: 10 capsules 
MaxEpa® 
 
1.8g EPA/day 
 
C: 10 capsules 
of olive oil 
 
I & C: 
Capsules 
contain 
peppermint 
oil 
 
Duration: 12 
weeks with 
assessments 
at 0, 4, 8 & 12 
weeks 
I: Percentage 
surface area 
affected 
showed a 
trend towards 
improvement. 
 
No significant 
change 
 
C: No change 
in placebo 
group. 
 
I: Significant 
improvement 
seen at weeks 
8 and 12. 
 
p < 0.05 
 
 
C: No change in 
the placebo 
group. 
Non-
response: 28 
(88%) and 24 
(75%) 
completed 
the 8 and 12 
weeks 
respectively.  
 
Compliance 
was 
satisfactory 
Average 
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after the trial in a subgroup of randomly selected patients by a nutritionist through a 48hr 
dietary recall.  There was no significant difference in PASI score and clinical state between 
the groups at baseline and no significant change in score was seen in either group after one, 
two, three and four months.  
 
Quality assessment 
 
Søyland et al (14) conducted a four-month-double-blind multicenter trial that was assessed to 
be of high quality. The population size and duration were adequate and the blinding of the 
subjects and clinicians was sufficient. Even though the number of subjects that did not finish 
the trial was high (24%), reasons for this were well described and found acceptable. 
Compliance was high and the outcomes of interest were adequately reported.  
 
Table 3. Result of trial conducted by Søyland et al (14).  
C: Control; I: Intervention; PASI: Psoriasis Area and Severity index, RCT: Randomised controlled trial, 
SFA: Saturated fatty acids 
 
Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of 
psoriasis, Bjørneboe et al (15).  
The eight-week double-blind block randomized study conducted by Bjørneboe et al (15) 
investigated the effect of dietary supplementation with omega-3 fatty acids on clinical 
manifestations of psoriasis. 30 patients with stable psoriasis vulgaris were included in the 
trial. Patients who were on retinoid treatment, were taking warfarin or salicylic acid, had 
disease of the gastrointestinal tract or the liver were excluded. For two months prior to the 
trial all included subjects had stopped using topical treatments.  
 
The included patients were randomly assigned to either the intervention or the placebo group. 
The subjects in the intervention group daily received ten 1g capsules of fish oil MaxEpa
®
 
Author/s Study 
design 
Population Intervention Coverage Inflammation Other  Quality 
Søyland 
et al, 
1993, 
Norway  
Double-
blind 
multicenter 
RCT 
145 
patients 
with stable 
plaque 
psoriasis 
 
44 female 
80 male 
completed 
the trial 
 
Mean age 
47yrs 
I: 6 capsules  
of fish oil 
 
3g EPA/day 
 
C: 6 capsules 
of corn oil 
 
I & C: 21.6 IU 
of vitamin 
E/day 
 
Duration: 4 
months with 
assessments 
every month 
I: No 
significant 
change  
 
C: No 
significant 
change 
  
I: Minimal 
change seen 
Before  
3.8 ± 0.3  
After  
3.7 ± 0.3  
 
No significant 
change  
 
C: Small change 
seen 
Before 
4.0 ± 0.3  
After  
3.7 ± 0.3  
 
No significant 
change 
 
Non-
response: 
124 (86%) 
patients 
completed 
the trial 
 
Patients 
were advised 
to decrease 
intake of SFA 
during trial  
 
Compliance 
was 
satisfactory 
High 
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altogether containing 1.8g EPA whereas those in the placebo group received ten 1g capsules 
of olive oil/day. All capsules contained 1 IU of vitamin E, 100 IU of vitamin A and 10 IU of 
Vitamin D. Patients were instructed to keep their regular diet during the trial but were told 
not to consume cod liver oil. All patients were examined at baseline, after four and eight 
weeks by the same clinician. The outcome measures were erythema, infiltration, 
desquamation and area involved.  
 
27 subjects (90%) completed the trial. The three patients that dropped out had difficulties 
swallowing the capsules. Compliance was measured by capsule count as well as by 
measuring the serum phospholipid fatty acid composition at baseline and after eight weeks.  
 
No significant difference, with respect to clinical scores for psoriasis, was seen between the 
two groups at baseline or during the trial.  
 
Quality assessment 
The quality of the double-blind block randomized controlled study conducted by Bjørneboe 
et al (15) was, assessed according to GRADE, classed as average. The intervention group and 
the placebo group were compared and were similar at baseline. Subjects and clinicians were 
blinded and compliance was of a high level. A moderate amount of subjects (10%) did not 
finish the trial but acceptable reasons for this was stated. Furthermore, the outcomes of 
interest were satisfactorily reported.  However, as there were only 30 subjects and these were 
block randomized the quality of the results will be lower (22). Also, a duration as short as 
eight weeks lowers the quality of the trial as results may not present in such a short period of 
time. This decreased the overall quality of this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Result of trial conducted by Bjørneboe et al (15).  
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C: Control; I: Intervention; IU: International Unit; RCT: Randomised controlled trial 
 
Analysis of the outcomes 
The analysis of the outcomes is presented below in table 2. The inflammation was assessed to 
have a limited strength of evidence (++). The population size in two of the studies (13,15) 
was relatively small and the trials lasted for short durations, hence reducing their statistical 
power. Regarding the sympathy between the results, there were also some limitations. Two 
out of the three studies (14, 15) reach similar results seeing no significant change in 
inflammation between the intervention and placebo group. However, Bittiner et al (13) did 
see a significant improvement in inflammation. There were some limitations regarding 
publication bias as two of the trials were sponsored by 7 seas pharmaceuticals
®
. However, 
these limitations were not believed to degrade the strength of evidence further.  
 
Coverage was assessed as limited strength of evidence (++). The strength of evidence was 
weakened by the fact that coverage was not directly measured and only presented as a PASI-
score in one of the trials, this decreasing the strength of evidence. Further, the short durations, 
small population sizes and risk of publication bias were relevant for this outcome as well.  
 
 
 
 
 
 
Table 5. Analysis of the outcomes. 
Author/s 
 
Study 
design 
Population Intervention Coverage Inflammation Other  Quality 
Bjørneboe 
et al, 
1987, 
Norway  
Double-
blind 
block RCT 
30 patients 
with stable 
psoriasis 
vulgaris 
 
Mean age 
39.5yrs 
 
Range 17—
72yrs  
I: 10 capsules  
Of MaxEpa
®
, 
 
1.8g EPA/day 
 
C: 10 capsules 
of olive oil 
 
I & C: 10 IUs 
vitamin E, 
1000 IU 
vitamin A, 
100 IU 
vitamin D/day 
 
Duration: 8 
weeks with 
assessments 
after 4 and 8 
weeks 
Clinical scores 
I:  
Before 
Mean: 32 
Range 8-80 
After  
Mean: 33 
Range 8-80 
 
No significant 
change 
 
C:  
Before 
Mean: 36 
range: 10-80 
After 
Mean: 33 
range: 10-80 
 
No significant 
change 
Clinical scores 
I:  
Before 
Mean: 6.7 
Range 4-11 
After  
Mean: 6.6 
Range 4-12 
 
No significant 
change 
 
C:  
Before 
Mean: 6.2 
Range 2-11 
After  
Mean: 6.1 
Range 2-11 
 
No significant 
change 
Non-
response: 27 
(90%) 
patients 
completed 
the trial 
 
Compliance 
was 
satisfactory 
Average 
 15 
 
Outcome  No° of 
studies 
Internal 
validity 
Sympathy External 
validity 
Unsure 
foundation 
Strength 
of 
evidence 
Inflammation 
(erythema)  
3 RCT Certain 
limitations2 
Certain 
limitations3 
No 
limitations 
Certain 
limitations4 
Limited 
(++) 
Coverage 
(area) 
3 RCT Certain 
limitations1,2 
No 
limitations 
No 
limitations 
Certain 
limitations4 
Limited 
(++) 
1 Outcome of interest not directly measured, 2 Small study populations and short durations, 3 Results 
vary between the studies. 4 Risk of publication bias. 
 
Discussion 
 
Upon reviewing the three studies, only one produced a positive outcome regarding 
inflammation (13), whereas the other two did not show any significant change on either 
outcome in either group (14, 15). These results will be related to the fact that the studies vary 
in strength and composition of supplement, duration and group sizes.  
 
The subjects entered into the Bittiner et al (13) double-blind trial consumed either ten 1g 
capsules of fish oils containing 1.8g of EPA or 10g of olive oil. The finding that there was an 
improvement with fish oils regarding inflammation when compared to the placebo suggests 
that fish oils do have an anti-inflammatory effect in psoriasis. However, as this trial 
ultimately only looked at 24 patients for twelve weeks this trial is not believed to have 
statistical power. This is one of the reasons that this trial was assessed to be of average 
quality. A further weakness of this trial is the fact that the patients were assessed for 
erythema using a 0-5 grading scale. This is not further explained or specified and therefore 
we cannot directly draw comparisons between these results and those in the other trials (14, 
15) where the PASI is used. There are no significant clinical differences that would determine 
the outcome of this trial as no other high standard trials have shown similar results, and 
conclusions cannot be drawn from one single trial.    
 
The supplementation in Soyland et al (14) consisted of either six 1g capsules of ethyl esters 
of very-long-chain omega-3 fatty acids or the same amount of corn oil. The MaxEpa
®
 
capsules used in the other trials (13, 15) are also composed of ethyl esters of omega 3. The 6g 
of fish oils per day consumed by the intervention group contained 3g of EPA, almost twice as 
much as consumed in the other trials (13, 15). As this trial is the largest and longest lasting 
one, and as no significant improvement was seen in either outcome, this suggests that EPA 
does not have a significant effect in symptom improvement in psoriasis.  
 
All capsules contained 3.6 IU of vitamin E as an antioxidant to prevent the oils from 
becoming rancid, this adding up to 36 IU per day. As vitamin E has antioxidant properties 
that contribute to cell membrane stability, the possibility that this has affected the outcome of 
the intervention cannot be excluded (12).  
 
The patients in this trial were advised to limit their intake of saturated fat. This may have 
played a role in the outcome, as a diet high in saturated fats is associated with an increase in 
inflammation (24).  This may possibly have worsened the symptoms.  
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Further, the patients in the Soyland et al trial (14) were allowed to continue on using their 
current topical treatments. Patients in this group had previously been treating their psoriasis 
with various topical ointments for a long duration of time. However, no significant outcome 
had yet been demonstrated prior to the trial. Therefore, the addition of fish oil may possibly 
have demonstrated a positive outcome.   
 
The intervention group in the Bjorneboe et al (15) trial received ten 1g capsules of 
MaxEPA
®
, altogether consuming 18g of EPA/day. The control group consumed ten 1g 
capsules of olive oil/day. Each capsule contained 1 IU of vitamin E as an antioxidant, 100 IU 
vitamin A and 10 IU of Vitamin D. In total the subjects would have consumed 10 IU vitamin 
E, 1000 IU vitamin A and 100 IU vitamin D per day. The vitamin A translates to 
300mcg/day, when the daily recommendation in Sweden is 700-900mcg/day (28). As 
previously discussed, the antioxidant effect of vitamin E may have played a role in the 
outcome of this trial as well (12). In a review written by Rickets et al (17) looking at nutrition 
in psoriasis, the oral supplementation of Vitamin D was shown to have a positive effect in 
some patients with psoriasis, primarily those with vitamin D deficiency. In a 1-year cross-
sectional study conducted on 145 patients with chronic plaque psoriasis, 57.8% of these 
subjects were seen to be vitamin D deficient (21). As the three trials that were analyzed were 
conducted in countries with limited sunlight and the vitamin D status of the subjects was not 
reported or discussed in either trial, we cannot exclude the possibility that this has affected 
the results.  
 
The same review discusses that vitamin A derivatives applied topically, orally or 
intravenously may also potentially confer benefits in patients with psoriasis. This is important 
to keep in mind when interpreting the results seen in Bjorneboe et als trial (17).  
 
Two of the studies were conducted in Norway (14,15) and one in England (13). As the 
subjects most likely would have been locals, their lifestyles and eating habits most certainly 
may vary from each other. It is important to keep this in mind when interpreting the results, 
as it is likely that the subjects‟ previous diet may have affected the outcome of the trials. 
Overall, Scandinavian diets are higher in fish oils than those in the more southern parts of 
Europe, including the UK (14).  
 
The Placebo in the three trials was either corn oil or olive oil. These differ in the sense that 
corn oil is high in polyunsaturated fats (PUFA) whereas olive oil mainly consists of 
monounsaturated fats (MUFA) (18). 1g of olive oil contains 0.73g of MUFA whereas 1g of 
corn oil consists of 0.59g of PUFA (26). Further, corn oil has an omega-3 to omega-6 ratio of 
1:49 compared to the same ratio in olive oil, which is 13:3 (25). A high omega-3 to omega-6 
PUFA ratio is associated with anti-inflammatory effects (27). Omega-6 acids have been seen 
to produce pro-inflammatory metabolic responses, possibly resulting in a larger difference in 
the outcomes between the corn oil placebo group and the fish oil intervention group in (26).  
 
The patients were advised to limit their intake of saturated fat, which may have played a role 
in the outcome. A diet high in saturated fats is associated with an increase in inflammation, 
possibly worsening the symptoms of psoriasis (24).  
 
The durations of the trials also vary in length from eight weeks to four months. A short 
duration is likely to result in a poorer clinical outcome (17, 22). The trial lasting for four 
months (14) has greater statistical power than the other two (13, 15), as there was more time 
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for the subjects to present with any clinical improvement. As no significant improvement was 
seen in this trial (14), it suggests that fish oil does not improve symptoms in psoriasis.  
 
An important point to discuss is the fact that two of the studies (14, 15) are sponsored by 7 
seas pharmaceuticals
®
.  When clinical trials are sponsored it is important to keep in mind that 
there is a risk of publication bias (22). 7 seas pharmaceuticals
®
 may have influenced what 
was published and swayed the results for personal gain. There are moral concerns raised by 
sponsored research as the companies typically focus on generating profits, and sometimes 
their priority focus is not on the health of the patients but on making a profit (23).   
 
As the three trials have not demonstrated significant outcomes inflammation and coverage, 
trials with longer durations, higher doses and larger populations would ultimately provide 
more solid evidence for whether or not a supplementation of fish oils is recommended in 
psoriasis. Based on the trials that have been reviewed, as both positive and negative outcomes 
have been perceived, further research is required to solidify the effect of fish oil 
supplementation in psoriasis.  
 
Conclusion 
 
In conclusion, this review shows that there is limited (++) evidence for that a daily oral 
supplementation of fish oils improves either inflammation or coverage in psoriasis. As only 
one randomized controlled trial demonstrated an improvement of the disease state, and as this 
one only looked at a small population for a short period of time, there is not enough evidence 
to support oral supplementation of fish oils as a primary treatment of psoriasis.  
 
Based on current research, the clinical value of fish oil supplementation remains uncertain 
regarding psoriasis. Fish oil supplementation may possibly exert some positive effects when 
used in addition to established psoriatic therapies, but at present its use as an exclusive 
treatment is not justifiable. To see whether a supplementation of fish oils produces a clinical 
response, trials for longer periods of time and higher doses of fish oils are in demand. Further 
research in this area is needed.  
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